Documents obtained from Japanese regulatory agency reveal that Pfizer biodistribution studies showed that mRNA and spike proteins circulate widely throughout the body.
Dr Joseph Mercola
- Canadian immunologist and vaccine researcher Byram Bridle, Ph.D., has gained access to Pfizer’s biodistribution study from the Japanese regulatory agency. The research, previously unseen, demonstrates a huge problem with all COVID-19 vaccines
- The assumption that vaccine developers have been working with is that the mRNA in the vaccines would primarily remain in and around the vaccination site. Pfizer’s data, however, show the mRNA and subsequent spike protein are widely distributed in the body within hours
- This is a serious problem, as the spike protein is a toxin shown to cause cardiovascular and neurological damage. It also has reproductive toxicity, and Pfizer’s biodistribution data show it accumulates in women’s ovaries
- Once in your blood circulation, the spike protein binds to platelet receptors and the cells that line your blood vessels. When that happens, it can cause platelets to clump together, resulting in blood clots, and/or cause abnormal bleeding
- Pfizer documents submitted to the European Medicines Agency also show the company failed to follow industry-standard quality management practices during preclinical toxicology studies and that key studies did not meet good laboratory practice standards
The more we learn about the COVID-19 vaccines, the worse they look. In a recent interview1 with Alex Pierson (above), Canadian immunologist and vaccine researcher Byram Bridle, Ph.D., dropped a shocking truth bomb that immediately went viral, despite being censored by Google.
It also was featured in a “fact” check by The Poynter Institute’s Politifact,2 which pronounced Bridle’s findings as “false” after interviewing Dr. Drew Weissman,3 a UPenn scientist who is credited with helping to create the technology that enables the COVID mRNA vaccines to work. But, as you can see below, unlike Bridle, Politifact neglected to go beyond interviewing someone with such a huge stake in the vaccine’s success.